Supplemental material

BMJ Publishing Group Limited (BMJ) disclaims all liability and responsibility arising from any reliance placed on this supplemental material which has been supplied by the author(s)

BMJ Open Diab Res Care

Supplementary file 2: Uptake of insulin pumps and continuous glucose monitoring (CGM) systems depending on healthcare coverage or insurance reimbursement for diabetes technologies

	Universal/partial healthcare coverage	No healthcare coverage	P value	Private insurance companies cover/ reimburse	Private insurance companies do not cover/reimburse	P value
Use of insulin pump			< 0.0001			< 0.0001
• **Less than 10%**	11.8%	70.6%		20.6%	50.9%	
• **10-30%**	27.7%	4.7%		15.5%	20.8%	
• **30-50%**	33.6%	12.9%		32.0%	17.9%	
• **More than 50%**	26.9%	11.8%		32.0%	10.3%	
Agreement to start on insulin pump			<0.0001			< 0.0001
• **Less than 25%**	8.4%	47.6%		9.4%	38.7%	
• **25-50%**	21.8%	15.4%		22.9%	16.0%	
• **50-75%**	31.1%	22.6%		34.4%	20.7%	
• **More than 75%**	38.9%	14.3%		33.3%	24.5%	
Use of CGM systems			<0.01			<0.01
• **Less than 10%**	11.1%	47.7%		15.4%	43.9%	
• **10-30%**	14.8%	23.9%		13.5%	28.0%	
• **30-50%**	16.7%	14.8%		19.2%	11.2%	
• **More than 50%**	57.4%	14.8%		51.9%	16.8%	
Agreement to start on CGM system			<0.01			<0.01
• **Less than 25%**	3.7%	32.6%		9.8%	28.3%	
• **25-50%**	16.7%	20.9%		11.8%	20.7%	
• **50-75%**	20.4%	26.7%		31.4%	27.4%	
• **More than 75%**	59.3%	19.8%		47.1%	23.6%	
Reason why patients turndown technology:			<0.0001			0.03
• **Family preference for keeping on injections and fingersticks**	7.5%	4.7%		8.2%	4.7%	
• **Fear**	4.2%	3.5%		3.1%	4.7%	
• **Parents cannot afford or maintain therapy**	17.5%	57.6%		26.5%	41.5%	
• **Patient does not want to wear something on its body**	65.8%	28.2%		58.2%	42.4%	

Supplemental material

BMJ Publishing Group Limited (BMJ) disclaims all liability and responsibility arising from any reliance placed on this supplemental material which has been supplied by the author(s)

BMJ Open Diab Res Care

• **Unawareness of technologies**	3.3%	3.5%		1.0%	5.7%	
• **Reduced diabetes literacy**	0.8%	1.2%		2.0%	0	
• **Not available**	0.8%	1.2%		1.0%	0.9%	
Agreement with the statement "All patients, regardless of circumstance, should be offered insulin pump therapy"	85.2%	78.9%	0.12	85.0%	79.6%	0.13
Disagreement with the sentence "No patient, regardless of circumstance, should be offered insulin pump therapy"	87.3%	86.6%	0.70	86.2%	87.7%	0.88
Relevant factors when starting a patient on insulin pump [a]						
• **Extremely relevant:**						
○ **Age**	35.6%	31.9%	0.75	28.2%	39.4%	0.20
○ **History of severe hypoglycemia**	58.9%	55.1%	0.79	50.6%	62.8%	0.32
○ **Suboptimal glycemic control**	44.1%	35.6%	0.07	34.5%	44.8%	0.15
○ **Requirement of small dosage of insulin**	48.4%	51.1%	0.72	50.6%	49.0%	0.87
• **Fairly relevant:**						
○ **Patient or caregiver preference**	31.9%	38.9%	0.27	32.0%	39.1%	0.09
Contraindications to starting a patient on insulin pump [b]						
• **No contraindication:**						
○ **Age less than 3 years old**	86.3%	87.5%	0.62	87.2%	86.7%	0.08
○ **One or more episodes of diabetic ketoacidosis**	50.0%	48.0%	0.96	50.0%	48.1%	0.96
• **Relative contraindication**						
○ **History of infrequent glucose monitoring/no use of CGM**	46.1%	72.0%	0.007	55.4%	65.1%	0.07
○ **Inadequate**						

Supplemental material

BMJ Publishing Group Limited (BMJ) disclaims all liability and responsibility arising from any reliance placed on this supplemental material which has been supplied by the author(s)

BMJ Open Diab Res Care

parental/caregiver supervision	45.9%	56.0%	0.47	53.4%	48.7%	0.41
• **Absolute contraindication:**						
○ **Infrequent follow-up**						
	48.7%	49.4%	0.13	41.6%	56.2%	0.17

a. On a scale from not at all relevant to extremely relevant, data were assessed for the most indicated option.

b. On a scale from not at all a contra-indication to an absolute contra-indication, data were assessed for the most indicated option.